Literature DB >> 8151374

Prognostic value of normal technetium-99m-sestamibi cardiac imaging.

K A Brown1, E Altland, M Rowen.   

Abstract

UNLABELLED: The purpose of this study was to describe the clinical outcome of patients with a normal 99mTc-sestamibi cardiac imaging study.
METHODS: One-day gated rest-stress planar dipyridamole (n = 112) and symptom-limited exercise (n = 122) 99mTc-sestamibi protocols were used. All patients (n = 234, mean age 55 +/- 12 yr, 127 males and 107 females) had normal perfusion and wall motion on qualitative analysis. Patients were followed for 6-16 mo (mean 10 +/- 2 mo). Cardiac events were defined as cardiac death or nonfatal myocardial infarction.
RESULTS: ST-segment depression or chest pain occurred in 8 (7%) and 29 (26%) patients in the dipyridamole group, respectively, and 20 (16%) and 28 (22%) patients in the exercise group. Cardiac events occurred in only one patient. The annualized event rate was 0.5% per year. In addition, only two patients underwent coronary revascularization during the follow-up period.
CONCLUSIONS: Our data confirm the benign outcome of patients with normal 99mTc-sestamibi cardiac imaging, at least over an intermediate follow-up period.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8151374

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  31 in total

1.  The clinical value of single photon emission computed tomography myocardial perfusion imaging in cardiac risk stratification of very elderly patients (≥80 years) with suspected coronary artery disease.

Authors:  Sanjeev U Nair; Alan W Ahlberg; Shishir Mathur; Deborah M Katten; Donna M Polk; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2011-11-10       Impact factor: 5.952

2.  A randomized trial of exercise treadmill ECG versus stress SPECT myocardial perfusion imaging as an initial diagnostic strategy in stable patients with chest pain and suspected CAD: cost analysis.

Authors:  Nikant K Sabharwal; Boyka Stoykova; Anil K Taneja; Avijit Lahiri
Journal:  J Nucl Cardiol       Date:  2007-04       Impact factor: 5.952

3.  A cost-effective sestamibi protocol in the managed health care era.

Authors:  E Milan; R Giubbini; G Gioia; A Terzi; A E Iskandrian
Journal:  J Nucl Cardiol       Date:  1997 Nov-Dec       Impact factor: 5.952

Review 4.  Pharmacologic stress versus maximal-exercise stress for perfusion imaging: which, when, and why?

Authors:  M D Cerqueira
Journal:  J Nucl Cardiol       Date:  1996 Nov-Dec       Impact factor: 5.952

5.  An incidental finding on myocardial perfusion imaging with a major impact in altering clinical management.

Authors:  Jarryd Whebell; Meroula Richardson; Benjamin Brady; Nathan Better
Journal:  J Nucl Cardiol       Date:  2017-03-17       Impact factor: 5.952

6.  Implementation of technetium-99m MIBI SPECT imaging guidelines: optimizing the two day stress-rest protocol.

Authors:  J M Lavalaye; J M Schroeder-Tanka; M M Tiel-van Buul; E E van der Wall; K I Lie; E A van Royen
Journal:  Int J Card Imaging       Date:  1997-08

7.  The site of acute myocardial infarction is related to the coronary territory of transient defects on prior myocardial perfusion imaging.

Authors:  J M Galvin; K A Brown
Journal:  J Nucl Cardiol       Date:  1996 Sep-Oct       Impact factor: 5.952

Review 8.  Role of myocardial perfusion imaging for risk stratification in suspected or known coronary artery disease.

Authors:  N K Sabharwal; A Lahiri
Journal:  Heart       Date:  2003-11       Impact factor: 5.994

9.  Prognosis in patients with left bundle branch block and normal dipyridamole thallium-201 scintigraphy.

Authors:  V M Gil; M Almeida; A Ventosa; J Ferreira; C Aguiar; J Calqueiro; R Seabra-Gomes
Journal:  J Nucl Cardiol       Date:  1998 Jul-Aug       Impact factor: 5.952

10.  Abnormal heart rate recovery immediately after treadmill testing: correlation with clinical, exercise testing, and myocardial perfusion parameters.

Authors:  Panagiotis Georgoulias; Alexandros Orfanakis; Nikolaos Demakopoulos; Petros Xaplanteris; Georgios Mortzos; Panos Vardas; Nikolaos Karkavitsas
Journal:  J Nucl Cardiol       Date:  2003 Sep-Oct       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.